Meridian Funds, managed by ArrowMark Partners, saw substantial gains in the third quarter despite emerging stagflation concerns. The Meridian Hedged Equity Fund returned 1.67% (net) compared to the S&P 500 Index’s 8.13% returns. Check out the fund’s top five holdings for 2025 insights.

Johnson & Johnson (NYSE: JNJ) was highlighted in the third-quarter 2025 investor letter by Meridian Hedged Equity Fund. The multinational healthcare company saw a one-month return of -0.43% and shares gained 41.09% over the last 52 weeks, closing at $205.78 per share on December 23, 2025.

Meridian Hedged Equity Fund praised Johnson & Johnson (NYSE: JNJ) in its investor letter, noting the company’s strategic execution amid patent expiration challenges. Positive developments in key drugs offset Stelara’s decline, boosting investor confidence. FDA approval for new treatments and improved trial data contributed to J&J’s success.

According to BofA, Johnson & Johnson (NYSE: JNJ) is not among the 30 most popular stocks among hedge funds. While acknowledging J&J’s potential, BofA believes certain AI stocks offer greater upside and lower downside risk. For those seeking undervalued AI stock opportunities, explore their free report.

Read more at Yahoo Finance: Here’s Why Johnson & Johnson (JNJ) Surged in Q3